Histology

AVANTIK EXPANDS SERVICE TO DIAGNOSTIC LABORATORIES NATIONWIDE

Retrieved on: 
Monday, December 18, 2023
Pathology, Laboratory, Patient, MTS, Dermatology, Histology

PINE BROOK, N.J., Dec. 18, 2023 /PRNewswire/ -- Avantik announced today that it has significantly expanded its service coverage to anatomic pathology, histology, and dermatology laboratories nationwide. The company has joined forces with CPBS Holdings and Marston Technical Services (MTS) to bolster its service hubs, resources, and technicians supporting diagnostic labs with maintaining their critical operations.

Key Points: 
  • Diagnostics Services Provider Joins Forces with CPBS Holdings & Marston Technical Services to Bolster Service Hubs, Technicians
    PINE BROOK, N.J., Dec. 18, 2023 /PRNewswire/ -- Avantik announced today that it has significantly expanded its service coverage to anatomic pathology, histology, and dermatology laboratories nationwide.
  • The company has joined forces with CPBS Holdings and Marston Technical Services (MTS) to bolster its service hubs, resources, and technicians supporting diagnostic labs with maintaining their critical operations.
  • With the addition of CPBS Holdings and MTS, Avantik more than doubles its geographic footprint, extending its service hubs into key markets across the United States.
  • CPBS Holdings and MTS will continue to serve customers under their current brands and structures as they transition to Avantik.

Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, November 13, 2023
NAFLD, Safety, SAN, Therapy, Cirrhosis, Clinical trial, Patient, DSM-IV codes, Diabetes, Lipid, Lipoprotein, Research, Liver injury, FDA, Extrapyramidal system, EFX, CMO, Biomarker, Fibrosis, AND, Histology, NASH, F4, Biopsy, Pharmaceutical industry, Medical imaging, Cryptocurrency, Åkerö

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported third quarter financial results for the period ending September 30, 2023 and provided business updates.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported third quarter financial results for the period ending September 30, 2023 and provided business updates.
  • Key secondary endpoints will include changes in biomarkers of liver fibrosis as well as measures of glycemic control and lipids.
  • Akero's cash, cash equivalents and short-term and long-term marketable securities for the period ended September 30, 2023 were $613.0 million.
  • Total operating expenses were $46.6 million for the three-month period ended September 30, 2023, compared to $36.1 million for the comparable period in 2022.

Madrigal Pharmaceuticals Presents New Data from the Phase 3 MAESTRO-NASH Trial Demonstrating Broad Treatment Effects of Resmetirom on Noninvasive Measures of Liver Health

Retrieved on: 
Friday, November 10, 2023
THR, Hepatology, MRE, AASLD, CAP, Hepatitis, Therapy, Incremental cost-effectiveness ratio, ELF, Fibrosis, Priority review, Treatment, Cirrhosis, Lipid, Division, Non-alcoholic fatty liver disease, Fatty liver disease, Atherosclerosis, Abstract, Diabetes, Histology, Biopsy, NDA, Electronic health record, ALT, Artificial intelligence, University, Marie Cassidy, NASH, Intelligence, Research, Disease, LDL, FDA, Radiation Exposure Compensation Act, Medical imaging, Pharmaceutical industry, Boston, Patient, Risk, Gastroenterology

Resmetirom is a liver-directed thyroid hormone receptor (THR)-β agonist oral therapy that is designed to target key underlying causes of NASH.

Key Points: 
  • Resmetirom is a liver-directed thyroid hormone receptor (THR)-β agonist oral therapy that is designed to target key underlying causes of NASH.
  • It is the only investigational therapy for NASH that has achieved both fibrosis improvement and NASH resolution primary endpoints in a Phase 3 trial.
  • Resmetirom also reduced levels of LDL cholesterol and other lipids that are associated with heart disease.
  • Resmetirom is an investigational therapy and has not been approved by the FDA or any other regulatory authority.

GH Research Reports Third Quarter Financial Results and Provides Business Updates

Retrieved on: 
Thursday, November 9, 2023
Feedback, Food, IND, Clinical trial, DSM-IV codes, Insurance, Patient, Research, FDA, GHRS, G&A, New Drug Application, Histology, TRD, Psychiatry, Rat, Letter, Pharmaceutical industry, Cryptocurrency

DUBLIN, Ireland, Nov. 09, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the third quarter ended September 30, 2023, and provided business updates.

Key Points: 
  • DUBLIN, Ireland, Nov. 09, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the third quarter ended September 30, 2023, and provided business updates.
  • R&D expenses were $7.1 million for the quarter ended September 30, 2023, compared to $4.6 million for the same quarter in 2022.
  • G&A expenses were $2.6 million for the quarter ended September 30, 2023, compared to $2.0 million for the same quarter in 2022.
  • Recently, the clinical research organization that manages one of our clinical trial sites informed us that the site will be closed for business reasons.

Long-Term Data for Kite’s Yescarta® CAR T-Cell Therapy Presented at ASH 2023 Demonstrate High Rate of Durable Response in Patients With High-Risk Large B-Cell Lymphoma

Retrieved on: 
Monday, December 11, 2023
Oncology, Health, Hospitals, Clinical Trials, Pharmaceutical, Biotechnology, BCL2, Fever, MYC, Progression-free survival, ASH, Aes, CRS, EFS, B-cell lymphoma, Headache, Cytopenia, Non-Hodgkin lymphoma, Patient, Abstract, PFS, DOR, BCL6, Histology, ORR, MD, Survival, Doctor of Philosophy, Drug, Society, OS, Confidence interval, Axicabtagene ciloleucel, SVP, Cytokine release syndrome, Pharmaceutical industry

“Patients with high-risk, large B-cell lymphoma, have a poor prognosis with currently available therapies,” said Julio C. Chavez, MD, lead investigator, Moffitt Cancer Center.

Key Points: 
  • “Patients with high-risk, large B-cell lymphoma, have a poor prognosis with currently available therapies,” said Julio C. Chavez, MD, lead investigator, Moffitt Cancer Center.
  • “This is particularly true of patients with double- or triple-hit histology, who have a median survival of under a year with standard treatment.
  • Prolonged cytopenias of any grade (present Day ≥30 post-infusion) occurred in 9 patients (n=7 neutrophil count decreased) and were resolved by data cutoff.
  • Among treated patients, the in vivo Yescarta expansion and persistence profiles are consistent with previous observations.

bioAffinity Technologies Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, November 14, 2023
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Sale, Lung, BIAF, Acquisition, Research, Exercise, CLIA, CAP, College, CPT, Patient, Clinical Laboratory, LDT, American Medical Association, Marketing, CMS, Lung cancer, Histology, Growth, Medicare, Gastric lavage, DOD, Physician, Military personnel, Observational study, Pharmaceutical industry, Medicaid

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other diseases of the lung, today reported financial results for the three and nine months ended Sept. 30, 2023, and provided a business update.

Key Points: 
  • bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other diseases of the lung, today reported financial results for the three and nine months ended Sept. 30, 2023, and provided a business update.
  • CMS is expected to finalize the 2024 payment for CyPath® Lung in November 2023 with an effective date of Jan. 1, 2024.
  • Clinical development expenses were $106,422 for the third quarter of 2023, compared with $60,941 for the third quarter of 2022.
  • Over the next 12 months (fourth quarter 2023 to third quarter 2024), the Company expects to generate between $8.4 and $9.0 million in net revenues.

Trial Library, oncology clinical trial technology company, announces release of provider decision support platform to advance access to trials in community oncology settings

Retrieved on: 
Thursday, December 7, 2023
Health equity, HIPAA, Research, SAN, Doctor of Pharmacy, Clinical trial, Genomics, Patient, Prostate cancer, PCF, Histology, Cancer, Death, ChromeOS, Medical imaging, Birth control

SAN FRANCISCO, Dec. 7, 2023 /PRNewswire/ -- Trial Library, Inc., an oncology clinical trials company, today announced it has launched a provider decision support platform to advance access to oncology clinical trials in community settings.

Key Points: 
  • SAN FRANCISCO, Dec. 7, 2023 /PRNewswire/ -- Trial Library, Inc., an oncology clinical trials company, today announced it has launched a provider decision support platform to advance access to oncology clinical trials in community settings.
  • The platform will support all oncology treatment clinical trials, and has provided an initial release to support prostate cancer trials.
  • This mismatch led Dr. Borno to develop an evidence-based technology solution for advancing access to oncology clinical trials.
  • Trial Library's provider decision support solution guides providers at the point of care to identify treatment clinical trials relevant for their patients.

Typenex® Medical Awarded Histology and Cytology Agreement with Premier, Inc.

Retrieved on: 
Wednesday, December 6, 2023
Collection, National Contract Management Association, Premier, Inc., Hospital, Searls, Organization, Histology

CHICAGO, Dec. 6, 2023 /PRNewswire/ -- Typenex® Medical LLC, a pioneer in histology and cytology solutions, has been awarded a national group purchasing contract with Premier, Inc. , a leading healthcare improvement company.

Key Points: 
  • CHICAGO, Dec. 6, 2023 /PRNewswire/ -- Typenex® Medical LLC, a pioneer in histology and cytology solutions, has been awarded a national group purchasing contract with Premier, Inc. , a leading healthcare improvement company.
  • This new agreement, effective as of February 1, 2024, allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier.
  • As an accredited diverse supplier, Typenex Medical is proud to deliver dedicated one-on-one customer service and extensive offerings of histology cassettes, inoculation loops, microscope slides, and other related products.
  • With this agreement, Premier members can easily secure enhanced tier pricing and exclusive benefits.

Elucid Raises $80 Million in Series C Round Led by Elevage Medical Technologies

Retrieved on: 
Thursday, November 9, 2023
Technology, Medical Devices, Finance, Health Technology, Professional Services, Cardiology, Software, General Health, Health, Artificial Intelligence, Ischemia, Stroke, FDA, Artery, Plaque, Marie Cassidy, Latham, Physician, Honigman LLP, Senior, Myocardial infarction, Partnership, Cardiovascular disease, Histology, Disability, Patient, Diagnosis, Death, Atherosclerosis, Quality management, Regulatory affairs, Medical device, Medical imaging, Elucid

Elucid , a leading medical technology company providing physicians with AI-powered imaging analysis software to assess cardiovascular disease, today announced it has raised $80 million in Series C funding.

Key Points: 
  • Elucid , a leading medical technology company providing physicians with AI-powered imaging analysis software to assess cardiovascular disease, today announced it has raised $80 million in Series C funding.
  • The round was led by Elevage Medical Technologies , with additional participation from industry strategics and existing investors.
  • This round brings the company’s total funding to $121 million since inception.
  • “Elevage believes leading this investment in Elucid is pivotal to support the development and commercialization of its groundbreaking diagnostic tools.

BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) of Adenocarcinoma Phenotype

Retrieved on: 
Wednesday, November 8, 2023
Adenocarcinoma, FDA, Intelligence, Taxane, Progression-free survival, Trial of the century, MCRPC, Lymph, Pembrolizumab, Data, Prostate cancer, Liver, BID, Phenotype, Disease, Rectum, Neoplasm, Partnership, Histology, September 6, RECIST, Tumor microenvironment, Safety, SCNC, Therapy, Patient, OS, CTC, Pharmaceutical industry, HAVEN

NEW HAVEN, Conn., Nov. 08, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced positive overall survival (OS) data from its Phase 2 trial of BXCL701, the Company's investigational oral innate immune activator, in combination with KEYTRUDA® (pembrolizumab) in patients with metastatic castration-resistant prostate cancer (mCRPC) of adenocarcinoma phenotype, the most common form of the disease. As of a September 6, 2023 data cutoff, evaluable patients with adenocarcinoma (n=29) showed a median OS of 15.5 months (95% CI 9.6–NR), and a 12-month survival rate of 59%.

Key Points: 
  • As of a September 6, 2023 data cutoff, evaluable patients with adenocarcinoma (n=29) showed a median OS of 15.5 months (95% CI 9.6–NR), and a 12-month survival rate of 59%.
  • “Therefore, we are highly encouraged by these combination data bearing in mind historical data with checkpoint inhibitor monotherapy.
  • Approximately 80% of mCRPC cases are of the adenocarcinoma phenotype, which represent approximately 46,128 patients.
  • The Company is continuing to actively evaluate strategic options for OnkosXcel Therapeutics, including potential financing, strategic partnership, or M&A.